Eberly Distinguished Lectureship in Immunology

Stanley R. Riddell, MD, professor of medicine at the University of Washington and associate program head of the Program in Immunology at the Fred Hutchinson Cancer Research Center, will be the first speaker in the 2016 Eberly Distinguished Lectureship in Immunology series. His talk, “Designing Safe and Effective T Cell Therapy for Cancer,” will take place at noon on Thursday, March 3, in Scaife Hall, Lecture Room 6.

Dr. Riddell received his MD from the University of Manitoba in Winnipeg, Canada, in 1979. After training in medicine and hematology at the University of Manitoba, he completed a fellowship in medical oncology and immunology at the University of Washington and the Fred Hutchinson Cancer Research Center.

Dr. Riddell is a leading researcher on T-cell therapy for cancer. His early research provided the first proof-of-principle that antigen-specific T cells could be isolated, expanded in the laboratory, and adoptively transferred to patients to successfully augment T-cell immunity to a virus. He and colleagues have developed widely used techniques for isolation, expansion, and genetic modification of T cells, as well as for monitoring safety, persistence, migration, and function after transfer. More recently, Dr. Riddell has applied chimeric antigen receptor (CAR)-modified T-cell products of defined subset composition in treatment of CD19+ malignancies, and he is developing new receptor constructs to allow T cells to target other cancers.

Dr. Riddell was a scientific founder of Juno Therapeutics, a joint venture launched in 2013 with scientists from the Fred Hutchinson Cancer Research Center, Seattle Children’s Research Institute, and Memorial Sloan Kettering Cancer Center that seeks to advance T-cell therapies for cancer treatment. In 2010, he was elected to the Association of American Physicians.